These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 10595802)

  • 1. Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer.
    Ignoffo RJ
    Am J Health Syst Pharm; 1999 Dec; 56(23):2417-28; quiz 2428-9. PubMed ID: 10595802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.
    Schmoll HJ
    Anticancer Drugs; 2003 Oct; 14(9):695-702. PubMed ID: 14551502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer.
    Cassata A; Procoplo G; Alù M; Ferrari L; Ferrario E; Beretta E; Longarini R; Busto G; De Candis D; Bajetta E
    Tumori; 2001; 87(6):364-71. PubMed ID: 11989587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cunningham D; Coleman R
    Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oral chemotherapy agents.
    Royce ME; Hoff PM; Pazdur R
    Curr Oncol Rep; 2000 Jan; 2(1):31-7. PubMed ID: 11122822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fluoropyrimidines: a closer look at their toxicities.
    Macdonald JS
    Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorouracil and the new oral fluorinated pyrimidines.
    Kuhn JG
    Ann Pharmacother; 2001 Feb; 35(2):217-27. PubMed ID: 11215843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
    Cunningham D; James RD
    Eur J Cancer; 2001 May; 37(7):826-34. PubMed ID: 11313169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoropyrimidines: a critical evaluation.
    Brito RA; Medgyesy D; Zukowski TH; Royce ME; Ravandi-Kashani F; Hoff PM; Pazdur R
    Oncology; 1999 Jul; 57 Suppl 1():2-8. PubMed ID: 10436410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral therapy for colorectal cancer: how to choose.
    Damjanov N; Meropol NJ
    Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral fluoropyrimidine treatment of colorectal cancer.
    Eng C; Kindler HL; Schilsky RL
    Clin Colorectal Cancer; 2001 Aug; 1(2):95-103. PubMed ID: 12445367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
    Omura K
    Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same.
    Mayer RJ
    J Clin Oncol; 2001 Nov; 19(21):4093-6. PubMed ID: 11689576
    [No Abstract]   [Full Text] [Related]  

  • 16. Practical considerations in the use of oral fluoropyrimidines.
    Hoff PM
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
    Diasio RB
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
    Folprecht G; Köhne CH
    Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of oral chemotherapy for colorectal cancer.
    Diasio RB
    Oncology (Williston Park); 2001 Mar; 15(3 Suppl 5):16-20. PubMed ID: 11301835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral fluoropyrimidines in colorectal cancer: a door open to the future?
    Delaunoit T; Neczyporenko F; Hendlisz A; Eisendrath P; Bleiberg H
    Acta Gastroenterol Belg; 2004; 67(4):331-3. PubMed ID: 15727077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.